Mediators of Inflammation
Volume 2012 (2012), Article ID 936721, 10 pages
http://dx.doi.org/10.1155/2012/936721
Review Article
Systemic Treatment of Vitreous Inflammation
Retina Division, Department of Ophthalmology, Wexner Medical Center at The Ohio State University, 915 Olentangy River Road, Suite 5000, Columbus, OH 43212, USA
Received 14 June 2012; Accepted 21 August 2012
Academic Editor: Mario R. Romano
Copyright © 2012 John B. Christoforidis et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Linked References
- C. S. Foster and A. T. Vitale, Diagnosis and Treatment of Uveitis, vol. 16, W.B. Saunders, Philadelphia, Pa, USA, 2002.
- D. A. Jabs and E. K. Akpek, “Immunosuppression for posterior uveitis,” Retina, vol. 25, no. 1, pp. 1–18, 2005. View at Publisher · View at Google Scholar · View at Scopus
- K. Kovacs, S. Wagley, M. T. Quirk et al., “Pharmacokinetic study of vitreous and serum concentrations of triamcinolone acetonide after posterior sub-tenon's injection,” American Journal of Ophthalmology, vol. 153, no. 5, pp. 939–948, 2012. View at Publisher · View at Google Scholar
- D. M. Albert and F. A. Jakobiec, Principles and Practice of Ophthalmology, W.B. Saunders, Philadelphia, Pa, USA, 2nd edition, 2000.
- N. A. Sabrosa and C. Pavésio, “Treatment strategies in patients with posterior uveitis,” International Ophthalmology Clinics, vol. 40, no. 2, pp. 153–161, 2000. View at Google Scholar · View at Scopus
- K. Durrani, F.R. Zakka, M. Ahmed, M. Memon, S.S. Siddique, and C.S. Foster, “Systemic therapy with conventional and novel immunomodulatory agents for ocular inflammatory disease,” Survey of Ophthalmology, vol. 56, no. 6, pp. 474–510, 2011. View at Publisher · View at Google Scholar
- A. A. Okada, “Immunomodulatory therapy for ocular inflammatory disease: a basic manual and review of the literature,” Ocular Immunology and Inflammation, vol. 13, no. 5, pp. 335–351, 2005. View at Publisher · View at Google Scholar · View at Scopus
- T. J. Zimmerman, Textbook of Ocular Pharmacology, vol. 29, Lippincott-Raven, Philadelphia, Pa, USA, 1997.
- S. Bom, P. Zamiri, and S. Lightman, “Use of methotrexate in the management of sight-threatening uveitis,” Ocular Immunology and Inflammation, vol. 9, no. 1, pp. 35–40, 2001. View at Publisher · View at Google Scholar · View at Scopus
- F. G. Holz, H. Krastel, A. Breitbart, M. Schwarz-Eywill, A. Pezzutto, and H. E. Völcker, “Low-dose methotrexate treatment in noninfectious uveitis resistant to corticosteroids.,” German Journal of Ophthalmology, vol. 1, no. 3-4, pp. 142–144, 1992. View at Google Scholar · View at Scopus
- A. Kaplan-Messas, Y. Barkana, I. Avni, and R. Neumann, “Methotrexate as a first-line corticosteroid-sparing therapy in a cohort of uveitis and scleritis,” Ocular Immunology and Inflammation, vol. 11, no. 2, pp. 131–139, 2003. View at Publisher · View at Google Scholar · View at Scopus
- S. S. Shah, C. Y. Lowder, M. A. Schmitt, W. S. Wilke, G. S. Kosmorsky, and D. M. Meisler, “Low-dose methotrexate therapy for ocular inflammatory disease,” Ophthalmology, vol. 99, no. 9, pp. 1419–1423, 1992. View at Google Scholar · View at Scopus
- S. Gangaputra, C. W. Newcomb, T. L. Liesegang et al., “Methotrexate for ocular inflammatory diseases,” Ophthalmology, vol. 116, no. 11, pp. 2188–e1, 2009. View at Publisher · View at Google Scholar · View at Scopus
- C. M. Samson, N. Waheed, S. Baltatzis, and C. S. Foster, “Methotrexate therapy for chronic noninfectious uveitis: analysis of a case series of 160 patients,” Ophthalmology, vol. 108, no. 6, pp. 1134–1139, 2001. View at Publisher · View at Google Scholar · View at Scopus
- M. E. Weinblatt, “Toxicity of low dose methotrexate in rheumatoid arthritis,” Journal of Rheumatology, vol. 12, supplement 12, pp. 35–39, 1985. View at Google Scholar · View at Scopus
- D. BenEzra and E. Cohen, “Cataract surgery in children with chronic uveitis,” Ophthalmology, vol. 107, no. 7, pp. 1255–1260, 2000. View at Publisher · View at Google Scholar · View at Scopus
- F. F. Lee and C. S. Foster, “Pharmacotherapy of uveitis,” Expert Opinion on Pharmacotherapy, vol. 11, no. 7, pp. 1135–1146, 2010. View at Publisher · View at Google Scholar · View at Scopus
- G. B. Elion, “Pharmacologic and physical agents. Immunosuppressive agents.,” Transplantation Proceedings, vol. 9, no. 1, pp. 975–979, 1977. View at Google Scholar · View at Scopus
- G. L. C. Chan, D. M. Canafax, and C. A. Johnson, “The therapeutic use of azathioprine in renal transplantation,” Pharmacotherapy, vol. 7, no. 5, pp. 165–177, 1987. View at Google Scholar · View at Scopus
- P. L. Hooper and H. J. Kaplan, “Triple agent immunosuppression in serpiginous choroiditis,” Ophthalmology, vol. 98, no. 6, pp. 944–952, 1991. View at Google Scholar · View at Scopus
- S. S. Michel, A. Ekong, S. Baltatzis, and C. S. Foster, “Multifocal choroiditis and panuveitis: immunomodulatory therapy,” Ophthalmology, vol. 109, no. 2, pp. 378–383, 2002. View at Publisher · View at Google Scholar · View at Scopus
- V. P. J. Saw, J. K. G. Dart, S. Rauz et al., “Immunosuppressive therapy for ocular mucous membrane pemphigoid. Strategies and outcomes,” Ophthalmology, vol. 115, no. 2, pp. 253–e1, 2008. View at Publisher · View at Google Scholar · View at Scopus
- J. K. Whisnant and J. Pelkey, “Rheumatoid arthritis: treatment with azathioprine (IMURAN (R)). Clinical side-effects and laboratory abnormalities,” Annals of the Rheumatic Diseases, vol. 41, supplement 1, pp. 44–47, 1982. View at Google Scholar · View at Scopus
- C. S. Foster and A. T. Vitale, “Immunosuppressive chemotherapy,” in Diagnosis and Treatment of Uveitis, C. S. Foster and A. T. Vitale, Eds., W.B. Saunders, Philadelphia, Pa, USA, 2002. View at Google Scholar
- D. Vavvas and C. S. Foster, “Immunomodulatory medications in uveitis,” International Ophthalmology Clinics, vol. 44, no. 3, pp. 187–203, 2004. View at Publisher · View at Google Scholar · View at Scopus
- A. C. Allison and E. M. Eugui, “Immunosuppressive and other effects of mycophenolic acid and an ester prodrug, mycophenolate mofetil,” Immunological Reviews, no. 136, pp. 5–28, 1993. View at Google Scholar · View at Scopus
- R. Voisard, S. Viola, V. Kaspar et al., “Effects of mycophenolate mofetil on key pattern of coronary restenosis: a cascade of in vitro and ex vivo models,” BMC Cardiovascular Disorders, vol. 5, no. 1, p. 9, 2005. View at Publisher · View at Google Scholar · View at Scopus
- S. Baltatzis, F. Tufail, E. N. Yu, C. M. Vredeveld, and C. S. Foster, “Mycophenolate mofetil as an immunomodulatory agent in the treatment of chronic ocular inflammatory disorders,” Ophthalmology, vol. 110, no. 5, pp. 1061–1065, 2003. View at Publisher · View at Google Scholar · View at Scopus
- L. Sobrin, W. Christen, and C. S. Foster, “Mycophenolate mofetil after methotrexate failure or intolerance in the treatment of scleritis and uveitis,” Ophthalmology, vol. 115, no. 8, pp. 1416–e1, 2008. View at Publisher · View at Google Scholar · View at Scopus
- D. A. Jabs, J. T. Rosenbaum, C. S. Foster et al., “Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel,” American Journal of Ophthalmology, vol. 130, no. 4, pp. 492–513, 2000. View at Publisher · View at Google Scholar · View at Scopus
- R. I. Fox, M. L. Herrmann, C. G. Frangou et al., “Mechanism of action for leflunomide in rheumatoid arthritis,” Clinical Immunology, vol. 93, no. 3, pp. 198–208, 1999. View at Publisher · View at Google Scholar · View at Scopus
- H. T. Silva Jr and R. E. Morris, “Leflunomide and malononitriloamides,” Expert Opinion on Investigational Drugs, vol. 6, no. 1, pp. 51–64, 1997. View at Publisher · View at Google Scholar · View at Scopus
- Anon, Leflunomide ADIS R&D Insight ADIS International, April 1998.
- R. P. Baughman and E. E. Lower, “Leflunomide for chronic sarcoidosis,” Sarcoidosis Vasculitis and Diffuse Lung Diseases, vol. 21, no. 1, pp. 43–48, 2004. View at Google Scholar · View at Scopus
- H. M. Roussel, Summary of Product Characteristics for Arava, Hoechst Marion Roussel, Uxbridge, UK, 1999.
- S. Cohen, G.W. Cannon, M. Schiff et al., “Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate,” Arthritis and Rheumatism, vol. 44, no. 9, pp. 1984–1992, 2001. View at Publisher · View at Google Scholar
- A. S. Fauci, S. M. Wolff, and J. S. Johnson, “Effect of cyclophosphamide upon the immune response in Wegener's granulomatosis.,” New England Journal of Medicine, vol. 285, no. 27, pp. 1493–1496, 1971. View at Google Scholar · View at Scopus
- C. E. Buckley III and J. P. Gills Jr, “Cyclophosphamide therapy of Behcet's disease,” Journal of Allergy, vol. 43, no. 5, pp. 273–283, 1969. View at Google Scholar · View at Scopus
- C. S. Foster, L. A. Wilson, and M. B. Ekins, “Immunosuppressive therapy for progressive ocular cicatricial pemphigoid,” Ophthalmology, vol. 89, no. 4, pp. 340–353, 1982. View at Google Scholar · View at Scopus
- W. M. Fosdick, J. L. Parsons, and D. F. Hill, “Long-term cyclophosphamide therapy in rheumatoid arthritis.,” Arthritis and Rheumatism, vol. 11, no. 2, pp. 151–161, 1968. View at Google Scholar · View at Scopus
- R. Brubaker, R. L. Font, and E. M. Shepherd, “Granulomatous sclerouveitis. Regression of ocular lesions with cyclophosphamide and prednisone,” Archives of Ophthalmology, vol. 86, no. 5, pp. 517–524, 1971. View at Google Scholar · View at Scopus
- A. S. Fauci, J. L. Doppman, and S. M. Wolff, “Cyclophosphamide-induced remissions in advanced polyarteritis nodosa,” American Journal of Medicine, vol. 64, no. 5, pp. 890–894, 1978. View at Google Scholar · View at Scopus
- T. Hoang-Xuan, C. S. Foster, and B. A. Rice, “Scleritis in relapsing polychondritis. Response to therapy,” Ophthalmology, vol. 97, no. 7, pp. 892–898, 1990. View at Google Scholar · View at Scopus
- K. Durrani, G. N. Papaliodis, and C. S. Foster, “Pulse IV cyclophosphamide in ocular inflammatory disease: efficacy and short-term safety,” Ophthalmology, vol. 111, no. 5, pp. 960–965, 2004. View at Publisher · View at Google Scholar · View at Scopus
- B. A. Chabner, P. C. Amrein, B. Druker et al., “Antineoplastic agents,” in Goodman & Gilman's the Pharmacological Basis of Therapeutics, L. S. Goodman, A. Gilman, L. L. Brunton, J. S. Lazo, and K. L. Parker, Eds., pp. 1315–1404, McGraw-Hill, New York, NY, USA, 2006. View at Google Scholar
- E. Miserocchi, S. Baltatzis, A. Ekong, M. Roque, and C. S. Foster, “Efficacy and safety of chlorambucil in intractable noninfectious uveitis: the Massachusetts eye and ear infirmary experience,” Ophthalmology, vol. 109, no. 1, pp. 137–142, 2002. View at Publisher · View at Google Scholar · View at Scopus
- A. B. Mudun, A. Ergen, S. U. Ipcioglu, E. Yarkin Burumcek, Y. Durlu, and M. Okan Arslan, “Short-term chlorambucil for refractory uveitis in Behcet's disease,” Ocular Immunology and Inflammation, vol. 9, no. 4, pp. 219–229, 2001. View at Publisher · View at Google Scholar · View at Scopus
- G. W. Cannon, C. G. Jackson, and C. O. Samuelson, “Chlorambucil therapy in rheumatoid arthritis: clinical experience in 28 patients and literature review,” Seminars in Arthritis and Rheumatism, vol. 15, no. 2, pp. 106–118, 1985. View at Google Scholar · View at Scopus
- K. F. Tabbara, “Chlorambucil in Behcet's disease. A reappraisal,” Ophthalmology, vol. 90, no. 8, pp. 906–908, 1983. View at Google Scholar · View at Scopus
- D. A. Gerber, C. A. Bonham, and A. W. Thomson, “Immunosuppressive agents: recent developments in molecular action and clinical application,” Transplantation Proceedings, vol. 30, no. 4, pp. 1573–1579, 1998. View at Publisher · View at Google Scholar · View at Scopus
- A. G. Palestine, R. B. Nussenblatt, and M. Gelato, “Therapy for human autoimmune uveitis with low-dose cyclosporine plus bromocriptine,” Transplantation Proceedings, vol. 20, no. 3, supplement 4, pp. 131–135, 1988. View at Google Scholar · View at Scopus
- A. T. Vitale, A. Rodriguez, and C. S. Foster, “Low-dose cyclosporine therapy in the treatment of birdshot retinochoroidopathy,” Ophthalmology, vol. 101, no. 5, pp. 822–831, 1994. View at Google Scholar · View at Scopus
- J. Liu, J. D. Farmer, W. S. Lane, J. Friedman, I. Weissman, and S. L. Schreiber, “Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes,” Cell, vol. 66, no. 4, pp. 807–815, 1991. View at Publisher · View at Google Scholar · View at Scopus
- M. Mochizuki, K. Masuda, T. Sakane et al., “A clinical trial of FK506 in refractory uveitis,” American Journal of Ophthalmology, vol. 115, no. 6, pp. 763–769, 1993. View at Google Scholar · View at Scopus
- D. J. Kilmartin, J. V. Forrester, and A. D. Dick, “Tacrolimus (FK506) in failed cyclosporin A therapy in endogenous posterior uveitis,” Ocular Immunology and Inflammation, vol. 6, no. 2, pp. 101–109, 1998. View at Publisher · View at Google Scholar · View at Scopus
- C. M. L. Sloper, R. J. Powell, and H. S. Dua, “Tacrolimus (FK506) in the treatment of posterior uveitis refractory to cyclosporine,” Ophthalmology, vol. 106, no. 4, pp. 723–728, 1999. View at Google Scholar · View at Scopus
- M. Naesens, D. R. J. Kuypers, and M. Sarwal, “Calcineurin inhibitor nephrotoxicity,” Clinical Journal of the American Society of Nephrology, vol. 4, no. 2, pp. 481–508, 2009. View at Publisher · View at Google Scholar · View at Scopus
- Y. Miwa, T. Isozaki, K. Wakabayashi et al., “Tacrolimus-induced lung injury in a rheumatoid arthritis patient with interstitial pneumonitis,” Modern Rheumatology, vol. 18, no. 2, pp. 208–211, 2008. View at Publisher · View at Google Scholar · View at Scopus
- M. M. O'Donnell, J. P. Williams, R. Weinrieb, and L. Denysenko, “Catatonic mutism after liver transplant rapidly reversed with lorazepam,” General Hospital Psychiatry, vol. 29, no. 3, pp. 280–281, 2007. View at Publisher · View at Google Scholar · View at Scopus
- V. A. Shanmuganathan, E. M. Casely, D. Raj et al., “The efficacy of sirolimus in the treatment of patients with refractory uveitis,” British Journal of Ophthalmology, vol. 89, no. 6, pp. 666–669, 2005. View at Publisher · View at Google Scholar · View at Scopus
- B. N. Phillips and K. J. Wroblewski, “A retrospective review of oral low-dose sirolimus (rapamycin) for the treatment of active uveitis,” Journal of Ophthalmic Inflammation and Infection, vol. 1, no. 1, pp. 29–34, 2011. View at Publisher · View at Google Scholar
- A. Reiff, “Long-term outcome of etanercept therapy in children with treatment-refractory uveitis,” Arthritis and Rheumatism, vol. 48, no. 7, pp. 2079–2080, 2003. View at Publisher · View at Google Scholar · View at Scopus
- P. P. Sfikakis, “Behçet's disease: a new target for anti-tumour necrosis factor treatment,” Annals of the Rheumatic Diseases, vol. 61, supplement 2, pp. ii51–ii53, 2002. View at Google Scholar · View at Scopus
- L. L. Lim, F. W. Fraunfelder, and J. T. Rosenbaum, “Do tumor necrosis factor inhibitors cause uveitis? A registry-based study,” Arthritis and Rheumatism, vol. 56, no. 10, pp. 3248–3252, 2007. View at Publisher · View at Google Scholar · View at Scopus
- A. Galor, V. L. Perez, J. P. Hammel, and C. Y. Lowder, “Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation,” Ophthalmology, vol. 113, no. 12, pp. 2317–2323, 2006. View at Publisher · View at Google Scholar · View at Scopus
- S. B. Desai and D. E. Furst, “Problems encountered during anti-tumour necrosis factor therapy,” Best Practice and Research, vol. 20, no. 4, pp. 757–790, 2006. View at Publisher · View at Google Scholar · View at Scopus
- N. Scheinfeld, “A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab,” Journal of Dermatological Treatment, vol. 15, no. 5, pp. 280–294, 2004. View at Publisher · View at Google Scholar · View at Scopus
- J. Lin, D. Ziring, S. Desai et al., “TNFalpha blockade in human diseases: an overview of efficacy and safety,” Clinical Immunology, vol. 126, no. 1, pp. 13–30, 2008. View at Publisher · View at Google Scholar
- L. H. Calabrese, “Molecular differences in anticytokine therapies,” Clinical and Experimental Rheumatology, vol. 21, no. 2, pp. 241–248, 2003. View at Google Scholar · View at Scopus
- B. Bodaghi, E. Bui Quoc, B. Wechsler et al., “Therapeutic use of infliximab in sight threatening uveitis: retrospective analysis of efficacy, safety, and limiting factors,” Annals of the Rheumatic Diseases, vol. 64, no. 6, pp. 962–964, 2005. View at Publisher · View at Google Scholar · View at Scopus
- R. P. Baughman, D. A. Bradley, and E. E. Lower, “Infliximab in chronic ocular inflammation,” International Journal of Clinical Pharmacology and Therapeutics, vol. 43, no. 1, pp. 7–11, 2005. View at Google Scholar · View at Scopus
- P. Kahn, M. Weiss, L. F. Imundo, and D. M. Levy, “Favorable response to high-dose infliximab for refractory childhood uveitis,” Ophthalmology, vol. 113, no. 5, pp. 864–e1, 2006. View at Publisher · View at Google Scholar · View at Scopus
- L. Niccoli, C. Nannini, M. Benucci et al., “Long-term efficacy of infliximab in refractory posterior uveitis of Behçet's disease: a 24-month follow-up study,” Rheumatology, vol. 46, no. 7, pp. 1161–1164, 2007. View at Publisher · View at Google Scholar · View at Scopus
- E. B. Suhler, J. R. Smith, T. R. Giles et al., “Infliximab therapy for refractory uveitis: 2-Year results of a prospective trial,” Archives of Ophthalmology, vol. 127, no. 6, pp. 819–822, 2009. View at Publisher · View at Google Scholar · View at Scopus
- J. Braun, J. Brandt, J. Listing et al., “Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial,” Arthritis and Rheumatism, vol. 48, no. 8, pp. 2224–2233, 2003. View at Publisher · View at Google Scholar · View at Scopus
- J. J. Gómez-Reino, L. Carmona, V. Rodríguez Valverde, E. M. Mola, and M. D. Montero, “Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report,” Arthritis and Rheumatism, vol. 48, no. 8, pp. 2122–2127, 2003. View at Publisher · View at Google Scholar · View at Scopus
- Z. Kaymakcalan, P. Sakorafas, S. Bose et al., “Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor,” Clinical Immunology, vol. 131, no. 2, pp. 308–316, 2009. View at Publisher · View at Google Scholar · View at Scopus
- B. Mushtaq, T. Saeed, R. D. Situnayake, and P. I. Murray, “Adalimumab for sight-threatening uveitis in Behçet's disease,” Eye, vol. 21, no. 6, pp. 824–825, 2007. View at Publisher · View at Google Scholar · View at Scopus
- M. Diaz-Llopis, S. García-Delpech, D. Salom et al., “Adalimumab therapy for refractory uveitis: a pilot study,” Journal of Ocular Pharmacology and Therapeutics, vol. 24, no. 3, pp. 351–361, 2008. View at Publisher · View at Google Scholar · View at Scopus
- J. P. Restrepo and M. P. Molina, “Successful treatment of severe nodular scleritis with adalimumab,” Clinical Rheumatology, vol. 29, no. 5, pp. 559–561, 2010. View at Publisher · View at Google Scholar · View at Scopus
- L. B. Vazquez-Cobian, T. Flynn, and T. J. A. Lehman, “Adalimumab therapy for childhood uveitis,” Journal of Pediatrics, vol. 149, no. 4, pp. 572–575, 2006. View at Publisher · View at Google Scholar · View at Scopus
- P. Tynjäaldie;, K. Kotaniemi, P. Lindahl et al., “Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis,” Rheumatology, vol. 47, no. 3, pp. 339–344, 2008. View at Publisher · View at Google Scholar · View at Scopus
- M. Rudwaleit, E. Rødevand, P. Holck et al., “Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study,” Annals of the Rheumatic Diseases, vol. 68, no. 5, pp. 696–701, 2009. View at Publisher · View at Google Scholar · View at Scopus
- J. A. Singh, G. A. Wells, R. Christensen et al., “Adverse effects of biologics: a network meta-analysis and Cochrane overview,” Cochrane Database of Systematic Reviews, vol. 2, p. CD008794, 2011. View at Google Scholar · View at Scopus
- A. Alonso-Ruiz, J. I. Pijoan, E. Ansuategui, A. Urkaregi, M. Calabozo, and A. Quintana, “Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety,” BMC Musculoskeletal Disorders, vol. 9, p. 52, 2008. View at Publisher · View at Google Scholar · View at Scopus
- H. Yang, J. Wang, J. Du et al., “Structural basis of immunosuppression by the therapeutic antibody daclizumab,” Cell Research, vol. 20, no. 12, pp. 1361–1371, 2010. View at Publisher · View at Google Scholar · View at Scopus
- L. Sobrin, J. J. Huang, W. Christen, C. Kafkala, P. Choopong, and C. S. Foster, “Daclizumab for treatment of birdshot chorioretinopathy,” Archives of Ophthalmology, vol. 126, no. 2, pp. 186–191, 2008. View at Publisher · View at Google Scholar · View at Scopus
- H. N. Sen, G. Levy-Clarke, L. J. Faia et al., “High-dose daclizumab for the treatment of juvenile idiopathic arthritis-associated active anterior uveitis,” American Journal of Ophthalmology, vol. 148, no. 5, pp. 696–e1, 2009. View at Publisher · View at Google Scholar · View at Scopus
- M. Gallagher, K. Quinones, R. A. Cervantes-Castañeda, T. Yilmaz, and C. S. Foster, “Biological response modifier therapy for refractory childhood uveitis,” British Journal of Ophthalmology, vol. 91, no. 10, pp. 1341–1344, 2007. View at Publisher · View at Google Scholar · View at Scopus
- P. Bhat, R. A. Castañeda-Cervantes, P. P. Doctor, and C. S. Foster, “Intravenous daclizumab for recalcitrant ocular inflammatory disease,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 247, no. 5, pp. 687–692, 2009. View at Publisher · View at Google Scholar · View at Scopus
- M. A. Rojas, N. G. Carlson, T. L. Miller, and J. W. Rose, “Long-term daclizumab therapy in relapsing-remitting multiple sclerosis,” Therapeutic Advances in Neurological Disorders, vol. 2, no. 5, pp. 291–297, 2009. View at Publisher · View at Google Scholar · View at Scopus
- L. Lim, E. B. Suhler, and J. R. Smith, “Biologic therapies for inflammatory eye disease,” Clinical and Experimental Ophthalmology, vol. 34, no. 4, pp. 365–374, 2006. View at Publisher · View at Google Scholar · View at Scopus
- F. Davatchi, H. Shams, M. Rezaipoor et al., “Rituximab in intractable ocular lesions of Behcet's disease; randomized single-blind control study (pilot study),” International Journal of Rheumatic Diseases, vol. 13, no. 3, pp. 246–252, 2010. View at Publisher · View at Google Scholar · View at Scopus
- S. R. J. Taylor, A. D. Salama, L. Joshi, C. D. Pusey, and S. L. Lightman, “Rituximab is effective in the treatment of refractory ophthalmic Wegener's granulomatosis,” Arthritis and Rheumatism, vol. 60, no. 5, pp. 1540–1547, 2009. View at Publisher · View at Google Scholar · View at Scopus
- C. S. Foster, P. Y. Chang, and A. R. Ahmed, “Combination of rituximab and intravenous immunoglobulin for recalcitrant ocular cicatricial pemphigoid. A preliminary report,” Ophthalmology, vol. 117, no. 5, pp. 861–869, 2010. View at Publisher · View at Google Scholar · View at Scopus
- A. Bermudez, F. Marco, E. Conde, E. Mazo, M. Recio, and A. Zubizarreta, “Fatal visceral varicella-zoster infection following rituximab and chemotherapy treatment in a patient with follicular lymphoma,” Haematologica, vol. 85, no. 8, pp. 894–895, 2000. View at Google Scholar · View at Scopus
- P. Quartier, O. Tournilhac, C. Archimbaud et al., “Enteroviral meningoencephalitis after anti-CD20 (rituximab) treatment.,” Clinical Infectious Diseases, vol. 36, no. 3, pp. e47–49, 2003. View at Google Scholar · View at Scopus
- Genentech, Products-Product Information-Immunology-Rituxan RA Full Prescribing Information, 2007-12-03.
- G. Jones, A. Sebba, J. Gu et al., “Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study,” Annals of the Rheumatic Diseases, vol. 69, no. 1, pp. 88–96, 2010. View at Publisher · View at Google Scholar · View at Scopus
- V. L. Perez, G. N. Papaliodis, D. Chu, F. Anzaar, W. Christen, and C. S. Foster, “Elevated levels of interleukin 6 in the vitreous fluid of patients with pars planitis and posterior uveitis: the Massachusetts eye & ear experience and review of previous studies,” Ocular Immunology and Inflammation, vol. 12, no. 3, pp. 193–201, 2004. View at Publisher · View at Google Scholar · View at Scopus
- A. Muselier, P. Bielefeld, S. Bidot, J. Vinit, J.-F. Besancenot, and A. Bron, “Efficacy of tocilizumab in two patients with anti-TNF-alpha refractory uveitis,” Ocular Immunology and Inflammation, vol. 19, no. 5, pp. 382–383, 2011. View at Publisher · View at Google Scholar
- V. Dinnendahl and U. Fricke, Arzneistoff-Profile, vol. 4, Govi Pharmazeutischer Verlag, Eschborn, Germany, 32 edition, 2010.
- V. Oldfield, S. Dhillon, and G. L. Plosker, “Tocilizumab a review of its use in the management of rheumatoid arthritis,” Drugs, vol. 69, no. 5, pp. 609–632, 2009. View at Publisher · View at Google Scholar · View at Scopus
- F. Hayden, “Antiviral agents (non-retroviral),” in Goodman & Gilman's the Pharmacological Basis of Therapeutics, L. S. Goodman, A. Gilman, L. L. Brunton, J. S. Lazo, and K. L. Parker, Eds., pp. 1243–1272, McGraw-Hill, New York, NY, USA, 2006. View at Google Scholar
- S. Mocellin, S. Pasquali, C. R. Rossi, and D. Nitti, “Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis,” Journal of the National Cancer Institute, vol. 102, no. 7, pp. 493–501, 2010. View at Publisher · View at Google Scholar · View at Scopus
- E. Alpsoy, C. Durusoy, E. Yilmaz et al., “Interferon alfa-2a in the treatment of Behçet disease: a randomized placebo-controlled and double-blind study,” Archives of Dermatology, vol. 138, no. 4, pp. 467–471, 2002. View at Google Scholar · View at Scopus
- I. Kotter, R. Vonthein, M. Zierhut et al., “Differential efficacy of human recombinant interferon-alpha2a on ocular and extraocular manifestations of Behcet disease: results of an open 4-center trial,” Seminars in Arthritis and Rheumatism, vol. 33, no. 5, pp. 311–319, 2004. View at Publisher · View at Google Scholar
- F. Mackensen, R. Max, and M. D. Becker, “Interferons and their potential in the treatment of ocular inflammation,” Clinical Ophthalmology, vol. 3, no. 1, pp. 559–566, 2009. View at Google Scholar · View at Scopus
- M. D. Becker, A. Heiligenhaus, T. Hudde et al., “Interferon as a treatment for uveitis associated with multiple sclerosis,” British Journal of Ophthalmology, vol. 89, no. 10, pp. 1254–1257, 2005. View at Publisher · View at Google Scholar · View at Scopus
- C. M. E. Deuter, M. Zierhut, A. Möhle, R. Vonthein, N. Stübiger, and I. Kötter, “Long-term remission after cessation of interferon-α treatment in patients with severe uveitis due to Behçet's disease,” Arthritis and Rheumatism, vol. 62, no. 9, pp. 2796–2805, 2010. View at Publisher · View at Google Scholar · View at Scopus
- I. Kotter, I. Günaydin, M. Zierhut, and N. Stübiger, “The use of interferon alpha in Behcet disease: review of the literature,” Seminars in Arthritis and Rheumatism, vol. 33, no. 5, pp. 320–335, 2004. View at Publisher · View at Google Scholar